Background {#Sec1}
==========

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease that is associated with aging and tobacco consumption; however, other exposures have also been causally related. Comorbidities contribute to the overall severity and economic burden of COPD \[[@CR1]\]. Among such comorbidities, anxiety and depression contribute to a substantial burden of COPD-related morbidity, notably by impairing quality of life and reducing adherence to treatment \[[@CR2]\]. In addition, recent studies have investigated the relationship between depression and anxiety with asthma, and they have shown that asthma is associated with depression and anxiety \[[@CR3]--[@CR5]\]. To date, most respiratory studies have included either patients with asthma alone (no COPD) or patients with COPD alone (no asthma) \[[@CR6]\]. However, patients older than 40 years may present with mixed features of both COPD and asthma, which has been called Asthma-COPD overlap (ACO) \[[@CR7]\]. Although previous studies have reported on the clinical features and poor outcomes of ACO \[[@CR8], [@CR9]\], there is still a debate over the defining features and disease severity of ACO \[[@CR10]\]. Nevertheless, one of the relevance of the ACO is to identify patients with COPD who may have underlying eosinophilic inflammation that responds better to inhaled corticosteroids \[[@CR9]\]. ACO can be useful for clinicians in terms of identifying patients with an expected poor outcome through overlapping clinical characteristics of asthma and COPD \[[@CR10], [@CR11]\]. Therefore, coexistence of asthma and COPD can serve as a criterion to assume ACO in a patient with COPD.

In 2017, the Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) committees released an updated document on the description of asthma-COPD overlap (ACO), which is characterized by persistent airflow limitation with several features usually associated with asthma and several features usually associated with COPD \[[@CR7]\]. Compared with patients with COPD alone, patients with ACO are often considered to have different clinical manifestations, with more respiratory symptoms (such as dyspnoea and wheezing), worse health-related quality of life, more frequent exacerbations, and more comorbidities \[[@CR12]--[@CR14]\]. A previous cohort study showed a higher risk of depression in the ACO cohort compared to non-ACO cohort (adjusted HR 1.67, 95% CI 1.48--1.88) \[[@CR15]\]. To avoid selection bias, the authors set a propensity score matched non-ACO cohort set as a comparison cohort using sex, age, and comorbidities; however, the difference in the use of ICS and oral steroid between the two cohorts remained significant. In addition, the socioeconomic status or health-care use have not been considered in the process of selecting non-ACO cohort. Therefore, selection bias still cannot be ruled out. In contrast, ACO and COPD share several common characteristics, including persistent airflow limitation and smoking, which comprise a critical diagnostic criterion and a source of these diseases, respectively \[[@CR7]\]. Considering that asthma is a heterogeneous disease that includes patients with wide variations in the age of onset, disease severity, pulmonary function, body mass index, presence of atopy, and Th2 eosinophil inflammation \[[@CR16]--[@CR18]\], the COPD alone cohort is likely to serve as a more appropriate comparison group to achieve clinically meaningful results.

In addition, treatment options and responses may differ depending on whether a patient has COPD alone or ACO \[[@CR9], [@CR19]\]; therefore, it is important to determine comorbidities associated specifically with ACO and COPD. Because mood disorder is a common comorbidity in chronic respiratory diseases, including asthma and COPD \[[@CR20]\], it is important to identify mood disorders and provide additional treatment to reduce the disease burden. However, unlike the prevalence of other comorbidities, the incidence of depression and anxiety among patients with ACO compared to COPD alone is little known. Therefore, we conducted a population-based retrospective cohort study to estimate the risks of depression and anxiety among patients with ACO and compared them with the risks among those with COPD alone.

Methods {#Sec2}
=======

Data source {#Sec3}
-----------

This study used the National Sample Cohort data from the National Health Insurance Service (NHIS--NSC) of Korea. The NHIS uses a systematic sampling approach to randomly select a representative population of approximately 1 million people between 2002 and 2013, which is 2.2% of the total population. The sample cohort was compared with the entire population with respect to the average total annual medical expenses, residence distribution, and the mean and standard deviation of health insurance premiums; the differences were negligible during the cohort years \[[@CR21]\]. The data gives researchers access to demographic data -- including sex, age recorded at 5--year intervals, income level, and date of death -- as well as the health care data -- including clinical diagnoses, medical procedures, expenditures, and drug prescriptions. Information on prescribed drugs included the generic drug name, prescription date, duration, and route of administration.

Study population {#Sec4}
----------------

To investigate the risk of depression and anxiety in patients with ACO and patients with COPD alone, we constructed a COPD cohort using National Sample Cohort data for the period between January 2003 and December 2011. The COPD cohort included patients older than 40 years who had been diagnosed with COPD at least twice as a principal or secondary diagnosis coded according to the International Classification of Disease, tenth revision (ICD-10 codes J42, J43, and J44) and with at least 1 prescription for ≥1 of the following COPD medications: inhaled corticosteroids (ICSs), inhaled long-acting β2-agonists (LABAs), an ICS and a LABA combined in a single inhaler (ICS/LABA), inhaled short-acting β2-agonists (SABAs), inhaled long-acting muscarinic antagonists (LAMAs), short-acting muscarinic antagonists (SAMAs), a SAMA and a SABA combined in a single inhaler (SAMA/SABA), oral leukotriene antagonists, xanthine derivatives, mast cell stabilizers, and systemic corticosteroids (CSs). Within the COPD cohort, patients were divided into ACO and COPD alone groups, based on the following asthma criteria: (1) diagnosis with asthma at least twice, as a principal or secondary diagnosis (ICD-10 codes J45 and J46); (2) at least one prescription for ≥1 of the following asthma medications: ICSs, LABAs, ICS/LABA, SABAs, oral leukotriene antagonists, xanthine derivatives, mast cell stabilizers, and systemic CSs. Patients who met both criteria for COPD and asthma were defined as ACO.

Patients were excluded from the analysis of the incidence of depression and anxiety if they were diagnosed with depression or anxiety within 1 year of the index date. A study flow chart is presented in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1The selection of study subjects. COPD, chronic obstructive pulmonary disease; ICD-10, International Classification of Diseases; ACO, asthma-COPD overlap

Follow-up to depression and anxiety {#Sec5}
-----------------------------------

We defined the outcome as time to first diagnosis with depression (ICD-10: F32 and F33) or anxiety (ICD-10: F40-F42) as the primary or secondary diagnosis after the index date. The index date was defined as the first date that both definitions of COPD and asthma were met. For example, if a patient with asthma met the definition of COPD later, the patient was considered eligible for inclusion in the ACO cohort from the day the patient met the definition of COPD. Patients with COPD alone were defined as those who met the definition of COPD but did not meet the definition of asthma, and the index date was defined as the first date when the patient met the definition of COPD. Follow-up was considered to have started on the index date and to have ended on the date of first diagnosis with depression or anxiety, the date the patient died, or 31 December, 2013 (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Design of the retrospective cohort study

Potential confounders {#Sec6}
---------------------

Age, sex, comorbidities, and concurrent medications are all possible confounders of the association between ACO or COPD and depression or anxiety. We calculated the Charlson comorbidity index to estimate the severity of disease according to previous diagnoses within one year before the index date. We selected as confounders any comorbidities that may influence the risk of depression or anxiety, which included hypertension, diabetes, hyperlipidaemia, ischaemic heart disease, sleep disorders, alcohol-related illnesses, epilepsy, cancer, arthritis, Parkinson's disease, dementia, obesity, cerebrovascular disease, and atherosclerosis \[[@CR22]\]. Concurrent medications were identified based on the prescriptions within 6 months before the date of each outcome to adjust the effect of using the medications just before the occurrence of the outcomes; in analysing the incidence of depression, we used the prescription information within 6 months before the date of depression, and in the same way, we used the prescription information within 6 months before the date of anxiety in analysing the incidence of anxiety. Benzodiazepines, digitalis, and calcium antagonists -- including diltiazem, nifedipine, and verapamil -- were selected as confounders because they were the frequently reported medications that might increase the risk of depression or anxiety \[[@CR23]\]. In addition, patients' history of exacerbation and healthcare utilization were also included as potential confounders. Within the ACO and COPD cohort, patients were classified by the frequency of exacerbations they experienced within one year before the index date: frequent (≥2), infrequent (1), and not exacerbated (0). Indicators for exacerbation were identified based on ICD codes (primary diagnosis) related to COPD (or asthma in ACO) present in combination with one of the following: (1) hospitalization, (2) emergency department visit, or (3) outpatient visit with either an oral corticosteroid or antibiotic prescription within 5 days of the visit \[[@CR24], [@CR25]\]. To take into account for healthcare use other than for exacerbation, we included non-exacerbation related healthcare use in the preceding year of the index date as a potential confounder, which was further classified by the type of healthcare use: (1) hospitalizations, (2) emergency department visit, or (3) outpatient visit.

Statistical analysis {#Sec7}
--------------------

We estimated the propensity scores for being defined as having ACO regardless of the outcomes by using multiple logistic regression analysis with the following variables: age category, sex, Charlson comorbidity index, history of comorbidities, exacerbations, and healthcare use in previous year, insurance type and index year. We assessed the model discrimination using the C statistic. Matching was performed using a Greedy 5 → 1 digit matching macro with the estimated propensity score \[[@CR26]\]. We used a standardized difference to compare baseline characteristics between patients with ACO and patients with COPD alone. We defined significant difference as an absolute value greater than 0.1 \[[@CR27]\].

We calculated the incidence rate per 1000 person-years by dividing the number of diagnoses of depression or anxiety by the total number of person-years at risk and multiplying the results by 1000. We also calculated the associated 95% confidence interval (CI). For construction of the multivariable model, we included the use of concurrent medications prescribed within 6 months before the date of the outcome as the adjusting variable. We used the Cox regression models to estimate the adjusted hazard ratios (aHRs) and their 95% CIs for depression and anxiety after adjusting for the concurrent medications in the propensity-based matched cohort.

We also conducted a subgroup analysis for the incidence of depression and anxiety according to age group, sex, comorbidities, and concurrent medications. We did subgroup analysis with interaction terms to see whether the association between ACO and incident depression or anxiety differed significantly by comorbidities and concurrent medications. All tests were 2-sided, with a significance level of 0.05. All data transformations and statistical analyses were conducted using SAS version 9.4 for Windows (SAS Institute, Cary, NC, USA).

Results {#Sec8}
=======

From the NHIS-NSC database, 28,116 COPD patients aged over 40 were diagnosed with COPD more than twice between January 2003 and December 2011. Of these, we identified 15,648 patients with ACO and 12,468 patients with COPD alone. After excluding patients who were diagnosed with anxiety or depression within 1 year before the index date, 12,866 patients were included in the initial cohort of ACO and 10,699 patients were included in the initial cohort of COPD alone. After propensity score estimation and matching in a one to one ratio, the cohort used in the analysis of depression and anxiety in patients with ACO versus patients with COPD alone included 15,644 patients (Fig. [1](#Fig1){ref-type="fig"}). Table [1](#Tab1){ref-type="table"} shows that clinical characteristics (age, sex, Charlson comorbidity index, history of comorbidities, exacerbations and healthcare use in previous year, insurance type, and index year) were not significantly different between patients with ACO and patients with COPD alone.Table 1Comparison of clinical characteristics between patients with ACO versus patients with COPD aloneCategoryNo. of patients (%)*P* valueStandardized difference^a^ACO (*n* = 7822)COPD alone (*n* = 7822)Age group (years) 40--643700(47.3)3718(47.53)0.77320.00461  ≥ 654122(52.7)4104(52.47)Sex Male4170(53.31)4176(53.39)0.92340.00154 Female3652(46.69)3646(46.61)Charlson comorbidity index 01436(18.36)1537(19.65)0.35010.03368 12645(33.81)2603(33.28) 21649(21.08)1642(20.99) 3877(11.21)855(10.93)  ≥ 41215(15.53)1185(15.15)History of comorbidities in previous year Hypertension2741(35.04)2671(34.15)0.23940.01881 Diabetes1558(19.92)1519(19.42)0.43280.01254 Hyperlipidaemia1319(16.86)1313(16.79)0.8980.00205 Ischaemic heart disease633(8.09)595(7.61)0.25860.01806 Sleep disorder600(7.67)559(7.15)0.21070.02001 Alcohol-related illness238(3.04)225(2.88)0.53970.00981 Epilepsy67(0.86)62(0.79)0.65850.00707 Cancer895(11.44)874(11.17)0.5960.00848 Arthritis1552(19.84)1537(19.65)0.76320.00482 Parkinson's disease41(0.52)42(0.54)0.91240.00176 Dementia72(0.92)86(1.1)0.26290.0179 Obesity3(0.04)7(0.09)0.20580.02023 Cerebrovascular disease621(7.94)606(7.75)0.65550.00713 Atherosclerosis168(2.15)160(2.05)0.65530.00714History of exacerbation in previous year 062(0.79)70(0.89)0.48440.01118 11636(20.92)1688(21.58)0.30950.01625  ≥ 26124(78.29)6064(77.52)0.24760.01849Healthcare utilization in previous year Hospitalization1327(16.96)1347(17.22)0.6710.00679 ED visit723(9.24)701(8.96)0.54090.00978 Outpatient visit7321(93.59)7302(93.35)0.53850.00983Insurance type Health insurance7529(96.25)7504(95.93)0.30220.0165 Medical-aid beneficiary293(3.75)318(4.07)Index year 20031483(18.96)1435(18.35)0.32450.01575 20041107(14.15)1032(13.19)0.08090.02791 2005910(11.63)943(12.06)0.41420.01306 2006847(10.83)916(11.71)0.08110.0279 2007765(9.78)816(10.43)0.17610.02163 2008770(9.84)809(10.34)0.30060.01655 2009768(9.82)714(9.13)0.14040.02358 2010565(7.22)547(6.99)0.57540.00896 2011607(7.76)610(7.8)0.92860.00143*ACO* asthma-COPD overlap, *COPD* chronic obstructive pulmonary disease, *ED* emergency department^a^A standardized mean difference of greater than 0.1 represents significant difference between the two cohorts

As shown in Table [2](#Tab2){ref-type="table"}, the incidence rate of depression was 44.0 per 1000 person-years in patients with ACO and 38.2 per 1000 person-years in patients with COPD alone. The crude HR of depression among patients with ACO was 1.15 (95% CI, 1.08--1.23). After adjustment for the medications prescribed within 6 months before the date of the outcome, the adjusted HR was 1.10 (95% CI, 1.03--1.18; *P* value = 0.0039). An increased risk of depression was observed among patients aged 40--64 years with an adjusted HR of 1.21 (95% CI, 1.10--1.34; P value = 0.0001), whereas the difference in risk among patients ≥65 years was not significant between patients with ACO and patients with COPD alone. In women, the risk of depression was higher in patients with ACO (aHR, 1.18; 95% CI, 1.07--1.29; *P* value = 0.0005); however, in men, the difference in risk between ACO patients and patients with COPD alone was not significant (aHR, 1.03; 95% CI, 0.93--1.13; *P* = 0.5718).Table 2Risk of depression and anxiety in patients with ACO versus patients with COPD aloneCategoryACO (*n* = 7822)COPD alone (*n* = 7822)Crude HR (95% CI)Adjusted^a^ HR (95% CI)*P* value for adjusted HREventsPYRateEventsPYRateDepression Overall190843,38044.0165443,34238.21.15(1.08--1.23)**1.10(1.03--1.18)0.0039**  Age groups (years)   40--64 (*n* = 7418)88622,40239.572722,81731.91.24(1.13--1.37)**1.21(1.10--1.34)0.0001**    ≥ 65 (*n* = 8226)102220,97848.792720,52545.21.08(0.99--1.18)1.01(0.93--1.11)0.7537  Sex   Male (*n* = 8346)87922,89138.479222,44835.31.09(0.99--1.20)1.03(0.93--1.13)0.5718   Female (*n* = 7298)102920,49050.286220,89441.31.22(1.11--1.33)**1.18(1.07--1.29)0.0005**Anxiety Overall301737,92779.5278038,15572.91.09(1.04--1.15)**1.06(1.01--1.12)0.0272**  Age groups (years)   40--64 (*n* = 7418)141619,66372.0131820,15565.41.10(1.02--1.19)**1.08(1.00--1.17)0.0392**    ≥ 65 (*n* = 8226)160118,26387.7146218,00081.21.08(1.00--1.16)1.04(0.97--1.11)0.3314  Sex   Male (*n* = 8346)139420,53667.9127220,46262.21.09(1.01--1.18)1.06(0.98--1.14)0.1349   Female (*n* = 7298)162317,39193.3150817,69385.21.09(1.02--1.17)1.06(0.99--1.14)0.0891Bold results represent statistically significant*ACO* asthma-COPD overlap, *COPD* chronic obstructive pulmonary disease, *PY* person-year; Rate, incidence rate (per 1000 person-years); HR, hazard ratio^a^Adjusted for medications - including calcium antagonists (diltiazem, nifedipine, verapamil), corticosteroids, digitalis, and benzodiazepines - prescribed within 6 months before the date of outcome

The incidence rate of anxiety was 79.5 per 1000 person-years in patients with ACO and 72.9 per 1000 person-years in patients with COPD alone. The crude HR of anxiety in patients with ACO was 1.09 (95% CI, 1.04--1.15). After adjustment for the medication prescribed within 6 months before the date of outcome, the adjusted HR was 1.06 (95% CI, 1.01--1.12; *P* value = 0.0272). In patients aged 40--64 years, the risk of anxiety in patients with ACO was significant when compared with that in patients with COPD alone (aHR, 1.08; 95% CI, 1.00--1.17; P value = 0.0392), and ACO patients ≥65 years also did not have a significantly higher risk of anxiety (aHR 1.04; 95% CI, 0.97--1.11; P value = 0.3314). The risk of anxiety was not significant in men (aHR, 1.06; 95% CI, 0.98--1.14; P value = 0.1349), nor in women (aHR, 1.06; 95% CI, 0.99--1.14; *P* value = 0.0891).

Table [3](#Tab3){ref-type="table"} shows the risk of depression in subgroups according to history of comorbidities in the previous year and use of concurrent medications within 6 months before the date of outcome. We found no difference in risk associated with the comorbidities and concurrent medications, except alcohol-related illness and use of corticosteroids. The hazard ratio was higher among patients with pre-existing alcohol-related illness than those without the illness (aHR, 2.12; 95% CI, 1.44--3.12 versus aHR, 1.08; 95% CI, 1.01--1.16; P value for interaction = 0.0008). Table [4](#Tab4){ref-type="table"} shows the risk of anxiety according to history of comorbidities in previous year and use of concurrent medications within 6 months before the date of outcome. Any comorbidities and concurrent medications did not increase the risk of anxiety.Table 3Subgroup analyses of risk of depression in patients with ACO versus patients with COPD aloneCategoryACO (*n* = 7822)COPD alone (*n* = 7822)Adjusted^a^ HR (95% CI)*P* value for interactionEventsPYRateEventsPYRateHistory of comorbidities in previous year Hypertension  Yes (*n* = 5412)71614,21450.462113,64145.51.05(0.94--1.17)0.2998  No (*n* = 10,232)119229,16640.9103329,70134.81.13(1.04--1.23) Diabetes  Yes (*n* = 3077)456796157.3367764248.01.10(0.96--1.27)0.9458  No (*n* = 12,567)145235,41941.0128735,70036.11.10(1.02--1.18) Hyperlipidemia  Yes (*n* = 2632)383642559.6337653851.51.13(0.98--1.31)0.6766  No (*n* = 13,012)152536,95541.3131736,80535.81.10(1.02--1.18) Ischaemic heart disease  Yes (*n* = 1228)181318956.8142281250.51.09(0.87--1.36)0.8601  No (*n* = 14,416)172740,19143.0151240,53037.31.10(1.03--1.18) Sleep disorder  Yes (*n* = 1159)228275082.9187254673.41.10(0.91--1.34)0.9332  No (*n* = 14,485)168040,63041.3146740,79636.01.10(1.03--1.18) Alcohol-related illness  Yes (*n* = 463)81120767.139131729.62.12(1.44--3.12)**0.0008**  No (*n* = 15,181)182742,17343.3161542,02638.41.08(1.01--1.16) Epilepsy  Yes (*n* = 129)2428983.11027136.92.11(1.00--4.45)0.0601  No (*n* = 15,515)188443,09243.7164443,07138.21.10(1.03--1.17) Cancer  Yes (*n* = 1769)271442661.2184424343.41.31(1.09--1.58)0.0562  No (*n* = 13,875)163738,95442.0147039,09937.61.07(1.00--1.15) Arthritis  Yes (*n* = 3089)442833353.0413815050.70.99(0.87--1.13)0.1019  No (*n* = 12,555)146635,04841.8124135,19235.31.14(1.06--1.23) Parkinson's disease  Yes (*n* = 83)1014469.3914163.70.59(0.22--1.60)0.5441  No (*n* = 15,561)189843,23643.9164543,20138.11.10(1.03--1.18) Dementia  Yes (*n* = 158)1522766.12222398.50.76(0.39--1.50)0.1681  No (*n* = 15,486)189343,15343.9163243,11937.81.11(1.04--1.18) Obesity  Yes (*n* = 10)0190.033586.61.99(NA)0.8967  No (*n* = 15,634)190843,36144.0165143,30838.11.10(1.03--1.18) Cerebrovascular disease  Yes (*n* = 1227)172286760.0157264259.40.96(0.77--1.20)0.1887  No (*n* = 14,417)173640,51442.8149740,70036.81.12(1.04--1.20) Atherosclerosis  Yes (*n* = 328)4775162.63372245.71.23(0.79--1.94)0.7111  No (*n* = 15,316)186142,63043.7162142,62038.01.10(1.03--1.18)Use of concurrent medications within 6 months before the date of outcomes Calcium antagonists  Yes (*n* = 892)149215069.3109179660.71.09(0.85--1.40)0.7505  No (*n* = 14,752)175941,23042.7154541,54637.21.10(1.03--1.18) Corticosteroids  Yes (*n* = 7658)119222,31453.484818,58045.61.15(1.05--1.26)0.1887  No (*n* = 7986)71621,06634.080624,76232.61.05(0.95--1.16) Digitalis  Yes (*n* = 509)67118656.551100750.71.11(0.77--1.61)0.9571  No (*n* = 15,135)184142,19443.6160342,33537.91.10(1.03--1.18) Benzodiazepines  Yes (*n* = 5425)109813,67180.394312,75074.01.08(0.99--1.18)0.2176  No (*n* = 10,219)81029,70927.371130,59323.21.14(1.03--1.26)Bold results represent statistically significant P value for interaction*ACO* asthma-COPD overlap, *COPD* chronic obstructive pulmonary disease, *PY* person-year; Rate, incidence rate (per 1000 person-years); HR, hazard ratio^a^Adjusted for medications - including calcium antagonists (diltiazem, nifedipine, verapamil), corticosteroids, digitalis, and benzodiazepines - prescribed within 6 months before the date of outcomesTable 4Subgroup analyses of risk of anxiety in patients with ACO versus patients with COPD aloneCategoryACO (*n* = 7822)COPD alone (*n* = 7822)Adjusted^a^ HR (95% CI)*P* value for interactionEventsPYRateEventsPYRateHistory of comorbidities in previous year Hypertension  Yes (*n* = 5412)111512,37290.199311,98482.91.06(0.97--1.15)0.977  No (*n* = 10,232)190225,55574.4178726,17168.31.06(0.99--1.13) Diabetes  Yes (*n* = 3077)654693894.3574675884.91.07(0.96--1.20)0.8967  No (*n* = 12,567)236330,98976.3220631,39770.31.06(1.00--1.12) Hyperlipidemia  Yes (*n* = 2632)5825597104.0514579788.71.12(1.00--1.27)0.2248  No (*n* = 13,012)243532,33075.3226632,35970.01.05(0.99--1.11) Ischaemic heart disease  Yes (*n* = 1228)273281996.8202251380.41.20(1.00--1.44)0.155  No (*n* = 14,416)274435,10878.2257835,64372.31.05(0.99--1.11) Sleep disorder  Yes (*n* = 1159)3142363132.92772095132.21.02(0.86--1.20)0.5789  No (*n* = 14,485)270335,56476.0250336,06069.41.06(1.01--1.12) Alcohol-related illness  Yes (*n* = 463)103115689.182111673.51.16(0.86--1.55)0.6018  No (*n* = 15,181)291436,77179.2269837,03972.81.06(1.00--1.12) Epilepsy  Yes (*n* = 129)2328680.51923680.61.12(0.60--2.11)0.9961  No (*n* = 15,515)299437,64179.5276137,92072.81.06(1.01--1.12) Cancer  Yes (*n* = 1769)351396288.6316371085.20.98(0.84--1.15)0.2878  No (*n* = 13,875)266633,96478.5246434,44571.51.07(1.01--1.13) Arthritis  Yes (*n* = 3089)7186980102.96906866100.51.00(0.90--1.10)0.1798  No (*n* = 12,555)229930,94774.3209031,29066.81.08(1.02--1.15) Parkinson's disease  Yes (*n* = 83)16118135.016125128.00.73(0.34--1.60)0.5775  No (*n* = 15,561)300137,80879.4276438,03072.71.06(1.01--1.12) Dementia  Yes (*n* = 158)20196102.224226106.41.19(0.64--2.22)0.7515  No (*n* = 15,486)299737,73179.4275637,93072.71.06(1.01--1.12) Obesity  Yes (*n* = 10)0190.0424167.41.12(NA)0.8607  No (*n* = 15,634)301737,90779.6277638,13172.81.06(1.01--1.12) Cerebrovascular disease  Yes (*n* = 1227)2572435105.5220238292.31.11(0.92--1.33)0.4783  No (*n* = 14,417)276035,49177.8256035,77371.61.06(1.00--1.11) Atherosclerosis  Yes (*n* = 328)7070199.95863391.60.98(0.69--1.41)0.5821  No (*n* = 15,316)294737,22679.2272237,52272.51.06(1.01--1.12)Use of concurrent medications within 6 months before the date of outcomes Calcium antagonists  Yes (*n* = 859)1991837108.31521494101.81.02(0.82--1.26)0.3769  No (*n* = 14,785)281836,09078.1262836,66271.71.06(1.01--1.12) Corticosteroids  Yes (*n* = 7552)176718,84893.7140515,79589.01.05(0.98--1.13)0.5356  No (*n* = 8092)125019,07965.5137522,36061.51.08(1.00--1.17) Digitalis  Yes (*n* = 511)92105487.37693980.91.12(0.82--1.53)0.9439  No (*n* = 15,133)292536,87379.3270437,21672.71.06(1.00--1.12) Benzodiazepines  Yes (*n* = 5245)151010,570142.9140010,238136.71.05(0.97--1.12)0.1742  No (*n* = 10,399)150727,35755.1138027,91749.41.08(1.01--1.16)*ACO* asthma-COPD overlap, *COPD* chronic obstructive pulmonary disease, *PY* person-year; Rate, incidence rate (per 1000 person-years); HR, hazard ratio^a^Adjusted for medications - including calcium antagonists (diltiazem, nifedipine, verapamil), corticosteroids, digitalis, and benzodiazepines - prescribed within 6 months before the date of outcome

Table [5](#Tab5){ref-type="table"} shows the association between the use of concurrent medications prescribed within 6 months before the date of depression or anxiety and the incidence of depression or anxiety. Among the frequently reported four types of medication that might increase the risk of depression or anxiety, calcium channel blocker, corticosteroid, and benzodiazepines were significantly associated with a higher incidence of depression or anxiety. Digitalis did not show a significant association with the incidence of depression or anxiety.Table 5Associations between the use of concurrent medications and incidence of mood disordersTypes of concurrent medications^a^DepressionAnxietyAdjusted^b^ HR (95% CI)*P* valueAdjusted^b^ HR (95% CI)*P* valueACO**1.10(1.03--1.18)0.00391.06(1.01--1.12)0.0272**Calcium channel blockers**1.30(1.15--1.48)\< 0.00011.14(1.02--1.27)0.018**Corticosteroids**1.20(1.12--1.28)\< 0.00011.19(1.13--1.26)\< 0.0001**Digitalis1.02(0.85--1.23)0.81390.88(0.75--1.02)0.098Benzodiazepines**2.92(2.73--3.13)\< 0.00012.54(2.41--2.68)\< 0.0001**Bold results represent statistically significant*ACO* asthma-COPD overlap, *COPD* chronic obstructive pulmonary disease, *HR* hazard ratio^a^Medications were considered as concurrent if they were prescribed within 6 months before the date of depression or anxiety^b^Adjusted for medications - including calcium antagonists (diltiazem, nifedipine, verapamil), corticosteroids, digitalis, and benzodiazepines - prescribed within 6 months before the date of outcome

Discussion {#Sec9}
==========

Principal findings {#Sec10}
------------------

In this population-based cohort study, we evaluated the association between ACO and the risk of depression and anxiety. Compared to patients with COPD alone, patients with ACO had a 1.10-fold increased risk of depression and 1.06-fold increased risk of anxiety. The risk of depression was higher in patients aged 40--64 years old and in women, but was not affected by presence of comorbidities within 1 year from the index date nor the use of concurrent medications within 6 months before the date of outcome, except the presence of alcohol-related illness. The risk of anxiety was higher in patients aged 40--64 years old, but was not affected by presence of comorbidities nor the use of concurrent medications. Our finding suggests that there is significant risk of depression and anxiety in patients with ACO compared with patients with COPD alone, irrespective of presence of comorbidities and use of concurrent medications.

Comparison with other studies {#Sec11}
-----------------------------

Our findings are consistent with a previous cohort study in that women and patients ≥65 years of age were found to have a higher rate of depression than men and patients \< 65 years of age \[[@CR15]\]. The higher incidence of depression in our Korean study population compared to that of in the Taiwanese population can be explained by the higher prevalence of mental disorders in Korea than in Taiwan \[[@CR28], [@CR29]\]. In addition, our results are also similar to those from a previous study which showed the risk of depression was greater in patient with alcohol-related illness \[[@CR15]\].

To date, our study is the first longitudinal study that has examined the incidence of anxiety disorders in patients with ACO. Our results with respect to the incidence of anxiety showed a higher rate of anxiety in women than in men, which is consistent with previously reported patterns of the prevalence of anxiety disorders in Korea \[[@CR30]\]. In addition, a retrospective cohort study has reported that anxiety is more prevalent in patients with ACO than in those with COPD alone, with an odds ratio of 1.18 (95% CI, 1.10--1.27) \[[@CR19]\]. Our results showed that the risk of anxiety is increased in patients with ACO compared with COPD alone. However, when we compared the risk of anxiety in ACO versus COPD patients in association with different treatments, the use of corticosteroid did not significantly increase the risk of anxiety. That is, the risk of anxiety in the patients with ACO, compared with patients with COPD alone, did not change with the use of corticosteroid.

Several studies have shown that patients with ACO have more severe respiratory symptoms, more frequent exacerbations and hospitalizations than those with COPD alone \[[@CR7], [@CR31]\]. In addition, COPD is treated mainly with bronchodilators, whereas ICS is recommended for the treatment of ACO patient with features of asthma \[[@CR7]\]. Therefore, patients with ACO are not only exposed to frequent use of systemic corticosteroids due to exacerbations, but they are also more treated with regular ICS, compared to those with COPD alone. Corticosteroids exposure leading to mood disorder can be explained by the fact that chronic corticosteroid use has been associated with alterations in central and peripheral serotonin levels \[[@CR32], [@CR33]\]. Further studies are needed to understand the mechanism behind the higher risk of mood disorder in patients with ACO compared to those with COPD.

Association between alcohol-related illness and higher incidence of depression in patients with ACO can be explained by a research that showed acetaldehyde causing bronchoconstriction indirectly via histamine-mediated process in asthma patients \[[@CR34]\]. Through the process of ethanol metabolism, mainly by aldehyde dehydrogenase (ALDH), ethanol is oxidized to acetaldehyde, which is further oxidized to acetate. However, many East Asian people were reported to be deficient in ALDH2, one of the ALDH isozymes \[[@CR35]\]. When they ingest ethanol, their blood acetaldehyde and histamine levels increase significantly due to insufficient metabolic activity, and the increased histamine may result in bronchoconstriction \[[@CR34], [@CR36]\]. Therefore, alcohol-related illnesses in ACO patients may cause more frequent exacerbations and lead to increased risk of depression. However, why the risk of anxiety was not affected by the presence of alcohol-related illness remains unexplained, and further studies are needed.

Previous studies have shown that mood disorders cause frequent exacerbations in asthma and COPD patients \[[@CR37], [@CR38]\]; this can be caused by the low compliance with medication \[[@CR39]\]. Anxiety and depression have also been associated with the activation of the hypothalamic-pituitary-adrenal axis \[[@CR40]\], which could increase the systemic inflammatory responses and increase the risk of exacerbation. Acute exacerbation is a key indicator for assessing the degree of disease control and prognosis in patients with chronic respiratory diseases such as asthma, COPD, and ACO, because it increases mortality and lowers the quality of life \[[@CR41], [@CR42]\]. When an impact of the 10% increase in the relative risk of the depression is estimated in each population of 10,000 patients with ACO and with COPD alone, 1000 patients with ACO will be at risk of developing depression, compared to those with COPD alone. A previous study showed that the rate of acute exacerbation in COPD patients with mood disorders increased by 56% compared to those without mood disorders \[[@CR38]\]. This suggests that additional 1000 ACO patients are at higher risk of developing acute exacerbations, leading to poor clinical prognosis. Therefore, our results demonstrate a need for clinicians to carefully examine for signs of mood disorders in addition to respiratory symptoms.

Strengths and limitations {#Sec12}
-------------------------

Our study has several strengths. First, to our knowledge, this is the first population-based cohort study comparing the risk of depression and anxiety between patients with ACO versus patients with COPD alone. The risk reported in previous studies was based on the comparison of patients with and without ACO, and the results showed there is a significant difference in the risk of depression between the two patient groups \[[@CR15]\]. However, our study revealed that the increased risk is also observed in patients with ACO when they are compared with patients with COPD alone; thus, providing a basis for the importance of monitoring and paying greater attention to the signs or symptoms of depression and anxiety in patients with ACO. Second, the use of a national sample cohort database was able to yield highly representative results and overcome the possible limitations (such as insufficient statistical power) arising from a small number of patients.

Certain potential limitations should be considered when interpreting our findings. The first limitation is the definition of ACO in our study, and because this is a very contentious area already, the ACO cohort in this study was based on a subset of the COPD cohort. There is no formal definition of ACO \[[@CR7]\]; therefore, we defined ACO based on the clinical diagnoses and corresponding prescribed medications. Although the definition of ACO has varied widely, the prevalence of ACO in our study is similar to that in previous studies \[[@CR8], [@CR12]\], which is estimated to be 52 to 55% of patients with COPD in database studies and 1.6 to 4.5% in the general population. The prevalence of ACO in our study was 56% (15,648/28,116) in patients with COPD and 1.4% (15,648/1,113,656) in the general population. Secondly, the measurement of outcomes was based on claims data, which does not capture patients with depression or anxiety that are not recorded in claims data (e.g. mild cases). Although there is a potential for inaccuracies in coding and for incompleteness of records, previous studies have validated the ICD-10 code-based definitions for diabetes and acute myocardial infarction (AMI), which were compared with medical records reviews and demonstrated positive predictive values of 72.3 to 87.2% for diabetes and \> 70% for AMI \[[@CR43], [@CR44]\]. Third, residual confounding may exist due to the observational nature of this study. Several variables that could have affected the outcomes were not fully captured in the database, including smoking status, family history of mental illness, disease duration or severity, education level, and income level.

Conclusions {#Sec13}
===========

The present study of a large population-based cohort study revealed that, compared with patients with COPD alone, patients with ACO have an increased risk of depression and anxiety.

ACO

:   Asthma-COPD overlap

COPD

:   Chronic obstructive pulmonary disease

CSs

:   corticosteroids

GINA

:   Global Initiative for Asthma

GOLD

:   Global Initiative for Chronic Obstructive Lung Disease

ICD-10

:   International Classification of Diseases, 10th revision

ICSs

:   inhaled corticosteroids

LABAs

:   long-acting β2-agonists

LAMAs

:   long-acting muscarinic antagonists

NHIS

:   National Health Insurance Service

NSC

:   National Sample Cohort data

SABAs

:   short-acting β2-agonists

SAMAs

:   short-acting muscarinic antagonists
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